There are 2934 resources available
New data for the early treatment of melanoma
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
Early treatment interactive discussion and Q&A
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
Survival data, subpopulations, and beyond: What’s new in the metastatic setting?
Presenter: Paolo Ascierto
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
Metastatic treatment interactive discussion and Q&A
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
Summary and close
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
Welcome and introduction
Presenter: Thomas Powles
Session: Bristol-Myers Squibb - Long-term experience and survival: An overview of I-O therapy in RCC and future research in GU cancers
Resources:
Webcast
4397 - An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies
Presenter: Thomas Powles
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
4844 - EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Presenter: Christopher Hoimes
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
2339 - Interferon ɣ (IFN-ɣ) gene signature and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression: a potential predictive composite biomarker for linrodostat mesylate (BMS-986205; indoleamine 2,3-dioxygenase 1 inhibitor [IDO1i]) + nivolumab (NIVO)
Presenter: Jason Luke
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
1691 - PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
Presenter: Benedetta Pellegrino
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast